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Human invasive breast cancers (IBCs) are categorized in
many ways, including on the basis of whether the tumour
cells express oestrogen receptor (ER)-α. ER status is impor-
tant clinically because ER mediates the growth-stimulating
effects of circulating oestrogen and because tumours
expressing ER have a significant chance of responding to
hormonal therapies such as tamoxifen and aromatase
inhibitors [1].
Epithelia in the normal breast nearly always contain a
subpopulation of ER-expressing cells [2,3]. The proportion of
positive cells is regulated physiologically and varies
considerably with menstrual status, averaging about 30%
overall [3]. About 75% of IBCs also contain a widely variable
proportion of ER-positive cells [1]. In contrast, the remaining
approximately 25% of IBCs do not contain any ER-positive
cells [1]. The origins of these entirely ER-negative tumours
have been the topic of considerable debate. Although there is
no consensus, the majority opinion on this issue appears to
be that ER-negative IBCs evolve from ER-negative pre-
cursors, whereas ER-positive IBCs evolve from ER-positive
precursors [4]. Many observations and assumptions support
the majority opinion, especially the following. First, studies
have suggested that tamoxifen prevents only ER-positive
IBCs in high-risk women [5]. Second, there is speculation
that the different so-called intrinsic subtypes of breast cancer,
some of which are entirely ER negative (for example, the
basal subtype), evolve from distinct types of stem/progenitor
cells [6]. Third, related research suggests that an ER-
negative stem cell is fundamentally responsible for normal
breast development, that they give rise to more differentiated
ER-positive progenitor cells, and that both may progress to
cancers with their corresponding ER phenotypes [7-10].
However, an alternative viewpoint, argued in this discussion,
is that there are multiple mechanisms for the development of
ER-negative IBCs, including many from ER-positive pre-
cursors by potentially reversible mechanisms. The importance
of this issue relates to the fact that ER-negative IBCs are
unresponsive to conventional hormonal therapies and that
finding strategies to convert them back to an ER-positive
phenotype, which is potentially responsive to these therapies,
would be a major contribution. Considerable evidence also
supports this alternative viewpoint (Table 1). For example,
epidemiological studies have demonstrated that increased
oestrogen exposure is a major risk factor for developing
breast cancer, presumably independent of ER status,
although the latter has not specifically been addressed in
these studies [11]. However, breast cancer was historically a
very rare disease, and the near epidemic increase in
incidence in Western cultures roughly corresponds to the
dramatic increase in oestrogen exposure, consistent with the
idea that oestrogen must contribute to the aetiology of all
breast cancers, including those that are ER-negative. Looked
at from the opposite direction, decreased oestrogen
exposure associated with prophylactic oophorectomy in
BRCA1 mutation carriers dramatically decreases the risk for
breast cancer, independent of ER status [12].
Histopathological studies also support the origin of ER-
negative IBCs from ER-positive precursors. For example,
nearly all well established premalignant lesions in the breast
are strongly ER positive [13], including atypical ductal
hyperplasia, and studies have shown that atypical ductal
hyperplasia is a strong risk factor for development of IBCs
independent of biological characteristics such as ER status
[14]. Furthermore, the proportions of ER-positive and ER-
negative IBCs decrease and increase with time, respectively.
This is consistent with progression of the latter from the
former. Perhaps the best illustration of this is the dramatic
decrease in ER-negative breast cancer since the introduction
of screening mammography (specifically, because of early
detection) [15,16]. Similarly, the proportion of ER-negative
tumours is substantially greater among large as compared
with small IBCs, and all large tumours were smaller at an
earlier point in time [16-19].
Although it is not widely appreciated, there is also
considerable intratumour histological and biological diversity
in breast cancers, arguing that ER-negative IBCs may evolve
from ER-positive precursors. For example, the majority of
IBCs appear to evolve from advanced precursor lesions,
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© 2007 BioMed Central Ltdreferred to as ductal carcinoma in situ (DCIS). The latter are
ER-positive in about 5% of ER-negative IBCs [20], which is
consistent with the idea that ER expression is suppressed
during tumour progression. Interestingly, the opposite is
almost never observed. Similarly, up to 20% of metastases
associated with ER-positive primary IBCs are ER negative,
which again is consistent with the idea that ER expression is
downregulated during tumour progression [21,22]. Recent
studies also show that the majority of DCISs contain cells of
diverse histological grades within individual tumours, and that
ER expression significantly decreases as grade increases in
these cells (as they become more poorly differentiated) [23].
In fact, most DCISs contain intratumour diversity for many
features, including histological grade, standard prognostic
biomarkers and even intrinsic subtypes, which is also
probably true for IBCs [23]. Presumably, these areas of
intratumour diversity compete for dominance, and eventually
the most aggressive prevail, which is a general mechanism by
which poorly differentiated (ER-negative) may gradually
evolve from well differentiated (ER-positive) tumours.
Several molecular mechanisms have recently been identified,
which may be involved in the loss of ER expression during
tumour progression. For example, recent studies have
demonstrated that hypermethylation of the ER promoter can
reversibly downregulate ER expression in IBCs [24]. Other
recent studies have shown that activation of the mitogen-
activated protein kinase pathway, especially through ligand-
activated tyrosine kinase receptors at the cell surface, can
downregulate ER expression in a reversible manner [25].
There is some evidence that even apparently normal physio-
logical responses retained by tumour cells can result in ER-
negative IBCs. For example, so-called apocrine metaplasia is
a common phenomenon in all types of benign breast
epithelia, and it is associated with a complete loss of ER
expression [26]. Apocrine metaplasia is also commonly
observed in breast cancers [26,27] and may be responsible
for the development of a substantial proportion of ER-
negative disease in a potentially reversible manner.
Overall, the evidence appears overwhelming that many ER-
negative IBCs evolve from ER-positive precursors, although it
also seems likely that some ER-negative IBCs may also
evolve from ER-negative precursors. Finding effective
therapies for these diverse types of ER-negative breast
cancers will be dependent on a comprehensive
understanding of the mechanisms that are responsible for
their development, and there are likely to be many.
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Table 1
Evidence supporting the origin of ER-negative breast cancers from ER-positive precursors
Evidence Details
Epidemiological Increased oestrogen exposure mediated by ER is a risk factor for all breast cancers
Prophylactic oophorectomy in BRCA1 mutation carriers reduces all breast cancers
ADH (>90% ER-positive cells) is a strong risk factor for all breast cancers
The proportion of ER-negative breast cancers increases with time (tumour progression)
Histological/pathological All early premalignant breast lesions are strongly ER positive
ER-positive precursors associated with ER-negative cancers in same breast/patient
Molecular MAPK activation reversibly transforms ER-positive to ER-negative breast cancers
Methylation ER promoter reversibly transforms ER-positive to ER-negative breast cancers
Apocrine metaplasia may reversibly transform ER-positive to ER-negative breast cancers
ADH, atypical ductal hyperplasia; ER, oestrogen receptor; MAPK, mitogen-activated protein kinase.Available online http://breast-cancer-research.com/content/9/S2/S20
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